Article thumbnail

The treatment of nephrotic syndrome caused by primary (light chain) amyloid with vincristine, doxorubicin and dexamethasone.

By A. M. Wardley, G. C. Jayson, D. J. Goldsmith, M. C. Venning, P. Ackrill and J. H. Scarffe

Abstract

Three out of four patients with primary (light chain) amyloid nephrotic syndrome treated with vincristine, doxorubicin and dexamethasone (VAD) induction obtained a partial response and are alive in continuing remission at 4.1, 6.5 and 9.3 years. These preliminary results are of considerable interest and suggest that prospective evaluation of this regimen is warranted in patients with this condition

Topics: Research Article
Publisher: Nature Publishing Group|1
OAI identifier: oai:pubmedcentral.nih.gov:2062981
Provided by: PubMed Central

Suggested articles


To submit an update or takedown request for this paper, please submit an Update/Correction/Removal Request.